Vyro Biotherapeutics Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Accelerator/Inc
- Latest Deal Amount
-
$900K
- Investors
-
2
Vyro Biotherapeutics General Information
Description
Developer of proprietary viral platforms intended to create advanced therapies for severe central nervous system diseases. The company offers genetically engineered Zika virus-based technologies including oncolytic virotherapies and virus-like particle systems for nucleic acid delivery, enabling patients with adult and pediatric CNS (Central Nervous System) tumors as well as genetic and rare neurological disorders to access targeted and scalable treatments.
Contact Information
Website
www.vyrobio.comCorporate Office
- Avenida Professor Lineu Prestes, 2242 - CIETEC - SALA 228
- Sao Paulo, São Paulo 05508-000
- Brazil
Corporate Office
- Avenida Professor Lineu Prestes, 2242 - CIETEC - SALA 228
- Sao Paulo, São Paulo 05508-000
- Brazil
Vyro Biotherapeutics Timeline
Vyro Biotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Accelerator/Incubator | 27-Feb-2026 | $900K | Completed | Startup | ||
| 4. Accelerator/Incubator | 31-Jan-2025 | Completed | Startup | |||
| 3. Accelerator/Incubator | 12-Jul-2024 | Completed | Startup | |||
| 2. Angel (individual) | 30-Apr-2024 | $900K | $2.4M | Completed | Startup | |
| 1. Seed Round | 01-Feb-2022 | $1.5M | $1.5M | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Vyro Biotherapeutics Patents
Vyro Biotherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025043010-A1 | Nucleic acid compositions for the generation of a zika virus-like particle | Inactive | 23-Aug-2023 | ||
| EP-4482862-A1 | Nucleic acid compositions for delivering exogenous polynucleotides and methods of use | Pending | 22-Feb-2022 | ||
| US-20250171802-A1 | Nucleic acid compositions for delivering exogenous polynucleotides and methods of use | Pending | 22-Feb-2022 | ||
| WO-2023164441-A1 | Nucleic acid compositions for delivering exogenous polynucleotides and methods of use | Inactive | 22-Feb-2022 | ||
| EP-4482505-A2 | Oncolytic viruses and methods of use | Pending | 22-Feb-2022 | C12N15/1135 |
Vyro Biotherapeutics Signals
Vyro Biotherapeutics Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Brazilian Center for Research in Energy and Materials (CNPEM) | Accelerator/Incubator | |||
| Vesper (Biotechnology) | Accelerator/Incubator | Minority |
Vyro Biotherapeutics FAQs
-
When was Vyro Biotherapeutics founded?
Vyro Biotherapeutics was founded in 2021.
-
Where is Vyro Biotherapeutics headquartered?
Vyro Biotherapeutics is headquartered in Sao Paulo, Brazil.
-
What is the size of Vyro Biotherapeutics?
Vyro Biotherapeutics has 5 total employees.
-
What industry is Vyro Biotherapeutics in?
Vyro Biotherapeutics’s primary industry is Drug Discovery.
-
Is Vyro Biotherapeutics a private or public company?
Vyro Biotherapeutics is a Private company.
-
What is Vyro Biotherapeutics’s current revenue?
The current revenue for Vyro Biotherapeutics is .
-
How much funding has Vyro Biotherapeutics raised over time?
Vyro Biotherapeutics has raised $3.5M.
-
Who are Vyro Biotherapeutics’s investors?
Brazilian Center for Research in Energy and Materials (CNPEM) and Vesper (Biotechnology) have invested in Vyro Biotherapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process